Investment
Features
FeesSafety
Academy
More
Pluang+

XRP Ledger patches new lending protocol before launch to fix code issues and prevent risks.

Protocol Fundamentals
19 Oct 2026
Decrypt
View Source
Neutral
XRP Ledger patches new lending protocol before launch to fix code issues and prevent risks.

XRP Ledger developers are fixing their new lending protocol with a follow-up amendment before it goes live, addressing issues in the original code while it is still in the network's voting queue. This protocol enables fixed-term, uncollateralized loans using pooled funds and relies on off-chain borrower vetting and "first-loss capital" to cover defaults, differing from typical DeFi collateral models. The patching approach avoids launching a flawed system and follows a recent critical bug fix in the ledger's payment engine that could have allowed counterfeit XRP creation. This cautious step is part of XRP Ledger's broader effort to build credit and DeFi capabilities for institutional-style finance.

XRP Ledger's lending protocol update comes as a backdrop to a broadly positive market for major cryptocurrencies on Pluang. For readers following the crypto sector, here is Pluang's market snapshot as of Oct 20, 2026 03:42 WIB: out of 50 major cryptocurrencies, 46 rose and 3 fell today. Notable movers include UNI (Uniswap) with a price of Rp129.807 and a 1-day change of +5.93%, SNX (Synthetix) at Rp3.868 up 5.54%, and SUSHI (SushiSwap) priced at Rp3.877 with a 5.17% increase. Typical hold times range from 65 to 102 days, with varied Pluang order activity percentages.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App